Related references
Note: Only part of the references are listed.TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats
Mingli Wang et al.
HEART AND VESSELS (2023)
Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence
Chrysi Koliaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Patients after Acute Stroke: Relation to Stroke Severity, Myocardial Injury, and Impact on Prognosis
Michal Mihalovic et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Longitudinal Study Reveals Long-Term Proinflammatory Proteomic Signature After Ischemic Stroke Across Subtypes
Tara M. Stanne et al.
STROKE (2022)
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial
Joao Pedro Ferreira et al.
CLINICAL RESEARCH IN CARDIOLOGY (2021)
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study
Lars Wallentin et al.
PLOS MEDICINE (2021)
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
Martin Snajdauf et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
TRAIL induces proliferation in rodent pancreatic beta cells via AKT activation
Sevim Kahraman et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2021)
TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review
Katarzyna Kakareko et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?
Fubing Ouyang et al.
TRANSLATIONAL STROKE RESEARCH (2021)
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
From Stroke to Dementia: a Comprehensive Review Exposing Tight Interactions Between Stroke and Amyloid-β Formation
Romain Goulay et al.
TRANSLATIONAL STROKE RESEARCH (2020)
Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy
Mette Bjerre et al.
ATHEROSCLEROSIS (2020)
Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats
Yaohui Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Vascular transcriptome landscape of Trail-/- mice: Implications and therapeutic strategies for diabetic vascular disease
Sian P. Cartland et al.
FASEB JOURNAL (2020)
Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction
R. Edfors et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 Update From the GBD 2019 Study
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to pro-inflammatory stimuli
Hannah Forde et al.
PHYSIOLOGICAL REPORTS (2020)
Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study
Ae Ran Moon et al.
MEDICINE (2019)
Atrial Fibrillation and Diabetes Mellitus JACC Review Topic of the Week
Allen Wang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events
Isabel Goncalves et al.
STROKE (2019)
Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation
Miles A. Tanner et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation
Winnie Chua et al.
EUROPEAN HEART JOURNAL (2019)
Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease
Tobias Feldreich et al.
JOURNAL OF NEPHROLOGY (2019)
Osteoprotegerin Assessment Improves Prediction of Mortality in Stroke Patients
Jaroslaw Wajda et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2019)
TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis
Sian P. Cartland et al.
ISCIENCE (2019)
Circulating proteins as predictors of incident heart failure in the elderly
Markus Stenemo et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Follow-up Analysis of Serum TNF-Related Apoptosis-Inducing Ligand Protein and mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Ischemic Stroke
Kemal Ugur Tufekci et al.
FRONTIERS IN NEUROLOGY (2018)
TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro
Pradeep Manuneedhi Cholan et al.
FREE RADICAL BIOLOGY AND MEDICINE (2018)
Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease
Oluremi Ajala et al.
RESPIRATORY MEDICINE (2018)
GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction
Emma Skau et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction A Holistic Proteomic Approach
Camilla Hage et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2017)
Autophagy is a regulator of TRAIL-induced apoptosis in NSCLC A549 cells
Yuqing Chen et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2017)
Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes
Liqun Zhao et al.
SCIENTIFIC REPORTS (2017)
Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice
Sian P. Cartland et al.
SCIENTIFIC REPORTS (2017)
The walking dead: macrophage inflammation and death in atherosclerosis
Mary M. Kavurma et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand
Hanis H. Harith et al.
JOURNAL OF DIABETES (2016)
Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure
Marek Kuzniewski et al.
ADVANCES IN MEDICAL SCIENCES (2016)
Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System
Barbara Toffoli et al.
MEDIATORS OF INFLAMMATION (2016)
Comparative Evaluation of TRAIL, FGF-2 and VEGF-A-Induced Angiogenesis In Vitro and In Vivo
Sian P. Cartland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity
Yang Ho Kang et al.
ATHEROSCLEROSIS (2015)
Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke
Xudong Pan et al.
PLOS ONE (2015)
Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation
Krzysztof Rewiuk et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms
Belinda Ann Di Bartolo et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?
Susanne Elisabeth Hosbond et al.
ATHEROSCLEROSIS (2014)
TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling
Min Liu et al.
ATHEROSCLEROSIS (2014)
Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients
Guangda Xiang et al.
CLINICAL ENDOCRINOLOGY (2014)
Role of Osteoprotegerin and Its Gene Polymorphisms in the Occurrence of Left Ventricular Hypertrophy in Essential Hypertensive Patients
Anna Shen et al.
MEDICINE (2014)
TRAIL/DR5 Signaling Promotes Macrophage Foam Cell Formation by Modulating Scavenger Receptor Expression
Fang Fang Liu et al.
PLOS ONE (2014)
TRAIL Deficiency Contributes to Diabetic Nephropathy in Fat-Fed ApoE-/- Mice
Sian P. Cartland et al.
PLOS ONE (2014)
Changes and Prognostic Impact of Apoptotic and Inflammatory Cytokines in Patients Treated with Cardiac Resynchronization Therapy
Pavel Osmancik et al.
CARDIOLOGY (2013)
Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence
Spyridon Deftereos et al.
CLINICAL BIOCHEMISTRY (2013)
Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation
Hailong Cao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure
Bernhard Richter et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients
Pavel Osmancik et al.
PLOS ONE (2013)
Correction: TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL
Belinda A. Di Bartolo et al.
PLoS One (2013)
Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers
Hasan Onur Arik et al.
MEDICAL SCIENCE MONITOR (2013)
Comparison of Osteoprotegerin to Traditional Atherosclerotic Risk Factors and High-Sensitivity C-Reactive Protein for Diagnosis of Atherosclerosis
Rasmus Mogelvang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
S. Jouan-Lanhouet et al.
CELL DEATH AND DIFFERENTIATION (2012)
Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients
A. Bisgin et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
TRAIL shows potential cardioprotective activity
Barbara Toffoli et al.
INVESTIGATIONAL NEW DRUGS (2012)
Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: Mechanisms of PDGF-BB-mediated VSMC proliferation and migration
Nor Saadah M. Azahri et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ
S. Fossati et al.
CELL DEATH & DISEASE (2012)
Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults
Stefano Volpato et al.
ATHEROSCLEROSIS (2011)
TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice
Victoria Watt et al.
ATHEROSCLEROSIS (2011)
Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus
Naoya Kawano et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe-/- mice
B. A. Di Bartolo et al.
DIABETOLOGIA (2011)
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study
A. Vik et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial
Ragnhild Roysland et al.
AMERICAN HEART JOURNAL (2010)
Possible Role of Osteoprotegerin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand as Markers of Plaque Instability in Coronary Artery Disease
Olfat G. Shaker et al.
ANGIOLOGY (2010)
Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis
Pei-Lin Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Decreased Apoptosis following Successful Ablation of Atrial Fibrillation
Pavel Osmancik et al.
CARDIOLOGY (2010)
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke
J. K. Jensen et al.
JOURNAL OF INTERNAL MEDICINE (2010)
Association of serum TRAIL level with coronary artery disease
Katsuhito Mori et al.
THROMBOSIS RESEARCH (2010)
Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status
Eoin P. O'Sullivan et al.
THROMBOSIS RESEARCH (2010)
Prognostic value of apoptosis markers in advanced heart failure patients
Alexander Niessner et al.
EUROPEAN HEART JOURNAL (2009)
Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction
Jamille Fernandes Lula et al.
EUROPEAN JOURNAL OF HEART FAILURE (2009)
Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: Implications for TRAIL-based therapy in humans?
Anne Grosse-Wilde et al.
CANCER RESEARCH (2008)
TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-κB and induction of insulin-like growth factor-1 receptor
Mary M. Kavurma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Preferential existence of death-inducing proteins in the human cardiomyopathic left ventricle
Nduna Dzimiri et al.
JOURNAL OF SURGICAL RESEARCH (2007)
Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro
Federica Corallini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice
Paola Secchiero et al.
CIRCULATION (2006)
Enhanced T-cell expression of RANK ligand in acute coronary syndrome -: Possible role in plaque destabilization
WJ Sandberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE(-/-) mice
Brian J. Bennett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy
M Schoppet et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice - Potential role of chondrocyte-like cells
M Rattazzi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Involvement of death receptor signaling in mechanical stretch-induced cardiomyocyte apoptosis
XD Liao et al.
LIFE SCIENCES (2005)
Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure
T Ueland et al.
CIRCULATION (2005)
Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand
P Secchiero et al.
NEOPLASIA (2004)
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
T Ueland et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Tissue distribution of the death ligand TRAIL and its receptors
DC Spierings et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes
SE Lamhamedi-Cherradi et al.
DIABETES (2003)
TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells
JH Li et al.
JOURNAL OF IMMUNOLOGY (2003)
TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways
P Secchiero et al.
CIRCULATION (2003)
Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure
A Abbate et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Share Paper
